EGFR and lung adenocarcinoma: Based on extended research in lung adenocarcinoma, it is current knowledge that almost all EGFRex20ins confer in vitro and clinical resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) [67,68], although osimertinib had shown clinical efficacy against some of these mutations [69,70].